



FOR IMMEDIATE RELEASE

Toronto Stock Exchange Symbol: MS

BIOMS MEDICAL ANNOUNCES SECOND QUARTER 2009 RESULTS

Edmonton, Alberta, July 17, 2009 – **BioMS Medical Corp. (TSX: MS)**, a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the three and six months ended June 30, 2009.

“The pivotal phase III MAESTRO-01 trial has completed the last patient last visit, and we are expecting results from this study within the second half of this year. This is the first of our two pivotal trials evaluating dirucotide in patients with secondary progressive multiple sclerosis and with a positive outcome, our drug could represent a valuable new treatment for MS patients,” said Kevin Giese, President and CEO of BioMS Medical.

Currently, BioMS is conducting two pivotal clinical trials and one open-label follow-on trial of dirucotide for the treatment of secondary progressive MS (SPMS):

- **MAESTRO-01:** This pivotal phase III trial is being conducted in Canada and Western Europe, involving 611 SPMS patients at 47 trial sites in ten countries. The primary clinical endpoint for MAESTRO-01 (and MAESTRO-03) is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes.
- **MAESTRO-02:** Eligible patients who have successfully completed MAESTRO-01 may choose to receive dirucotide on an un-blinded basis in this open-label follow-on study regardless of whether they were previously on placebo or drug. To date, approximately 95% of the eligible patients who have successfully completed the MAESTRO-01 trial have enrolled in this follow-on study.
- **MAESTRO-03:** Enrollment was initiated in June 2007 and completed on August 1, 2008 for this pivotal U.S. phase III trial of approximately 510 SPMS patients at 67 sites across the U.S. To date, the DSMB has conducted four reviews of the data from this trial and recommended it continue.

Financial Results

The consolidated net income for the three months ended June 30, 2009 was \$1.5 million or \$0.02 per share compared with a consolidated net loss of (\$0.4) million or (\$0.00) per share for the previous year. The consolidated net income for the six months ended June 30, 2009 was \$0.1 million or \$0.00 per share compared with a consolidated net loss of (\$7.1) million or (\$0.08) per share for the same period in 2008.

Revenue earned from the collaboration agreement was \$11.9 million for the three months and \$25.0 million for the six months ended June 30, 2009 compared to \$11.2 million and \$24.0 million

for the three and six months ended June 30, 2008. This revenue is the result of the amortization of the upfront payment and development milestone payment received from Lilly, associated with the positive interim analysis of the MAESTRO-01 clinical trial.

Total consolidated expenses for the three months ended June 30, 2009 were \$10.3 million compared with \$11.4 million for the three months June 30, 2008. Expenses related to direct research and development efforts accounted for \$8.1 million or 79% of all expenses for the three months ended June 30, 2009 compared with \$9.3 million or 82% for this period in 2008. Total consolidated expenses for the six months ended June 30, 2009 were \$25.1 million as compared with \$33.6 million in the six months June 30, 2008. Expenses related to direct research and development efforts accounted for \$19.6 million or 78% of all expenses for the six months ended June 30, 2009 compared with \$22.5 million or 67% for this period in 2008.

As at June 30, 2009, cash and cash equivalents and short-term investments totaled \$67.5 million as compared to \$90.4 million at December 31, 2008. As at June 30, 2009, the Company had working capital of \$59.8 million as compared to \$81.3 million at December 31, 2008. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at June 30, 2009 there were 91,008,923 Class "A" common shares of the Company issued and outstanding.

About BioMS Medical Corp.

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an \$87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at <http://www.biomsmedical.com>

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, please contact:

Tony Hesby
Ryan Giese
Amanda Stadel

BioMS Medical Corp.

780-413-7152

780-408-3040 Fax

E-mail: info@biomsmedical.com

Internet: <http://www.biomsmedical.com>

James Smith

Investor Relations

416-815-0700 ext. 229

416-815-0080 Fax

E-mail: jsmith@equicomgroup.com

BioMS Medical Corp.
(A Development Stage Corporation)
Interim Consolidated Balance Sheets
(Unaudited)

(expressed in thousands of Canadian dollars)

	June 30, 2009 \$ (Unaudited)	December 31, 2008 \$
Assets		
Current assets		
Cash and cash equivalents	64,864	87,826
Short-term investments	2,652	2,614
Goods and services tax recoverable	65	299
Prepaid clinical trial costs	1,914	2,227
Other current assets	664	321
	<hr/> 70,159	<hr/> 93,287
Prepaid clinical trial costs	495	790
Licensing costs	5,174	5,910
Property and equipment	<hr/> 438	<hr/> 517
	<hr/> 76,266	<hr/> 100,504
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities	10,564	12,015
Deferred revenue	20,615	45,605
	<hr/> 31,179	<hr/> 57,620
Shareholders' Equity		
Share capital	175,714	175,714
Contributed surplus	10,937	8,839
Accumulated deficit	<hr/> (141,564)	<hr/> (141,669)
	<hr/> 45,087	<hr/> 42,884
	<hr/> 76,266	<hr/> 100,504

BioMS Medical Corp.

(A Development Stage Corporation)

Interim Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(expressed in thousands of Canadian dollars and shares, except per share amounts)

	Cumulative from inception to June 30,	Six-month period ended June 30,		Three-month period ended June 30,	
	2009 \$	2009 \$	2008 \$	2009 \$	2008 \$
Revenue earned from collaboration partner	77,551	24,990	24,000	11,933	11,231
Less: Research and development expenses	(171,732)	(19,647)	(22,482)	(8,138)	(9,339)
	(94,181)	5,343	1,518	3,795	1,892
General and administrative expenses	(47,215)	(4,610)	(10,388)	(1,762)	(1,693)
Amortization of licensing costs	(12,491)	(736)	(736)	(368)	(368)
Amortization of property and equipment	(602)	(85)	(43)	(42)	(31)
Income (loss) from operations	(154,489)	(88)	(9,649)	1,623	(200)
Other income (expense)					
Investment income	9,045	266	1,323	96	594
Foreign exchange gain (loss)	5,507	(73)	1,239	(215)	(796)
	14,552	193	2,562	(119)	(202)
Net income (loss) and comprehensive income (loss)	(139,937)	105	(7,087)	1,504	(402)
Basic and diluted net income (loss) per common share		0.00	(0.08)	0.02	0.00
Basic weighted average number of common shares outstanding		91,009	91,311	91,009	91,217
Diluted weighted average number of common shares outstanding		91,563	91,311	91,356	91,217

BioMS Medical Corp

(A Development Stage Corporation)

Interim Consolidated Statements of Cash Flows

(Unaudited)

(expressed in thousands of Canadian dollars)

	Cumulative from inception to June 30,	Six-month period ended June 30,		Three-month period ended June 30,	
	2009 \$	2009 \$	2008 \$	2009 \$	2008 \$
Cash provided by (used in)					
Operating activities					
Net income (loss)	(139,937)	105	(7,087)	1,504	(402)
Items not involving cash					
Stock-based compensation	10,976	2,098	2,168	-	264
Amortization of licensing costs	12,491	736	736	368	368
Amortization of property and equipment	602	85	43	42	31
Loss on disposal of property and equipment	11	-	7	-	2
	(115,857)	3,024	(4,133)	1,914	263
Net change in non-cash working capital items	23,628	(27,491)	61,986	(14,135)	(10,317)
	(92,229)	(24,467)	57,853	(12,221)	(10,054)
Investing activities					
Purchase of property and equipment	(1,052)	(7)	(29)	(6)	(29)
Net (purchase of) proceeds from short- term investments	(2,652)	(38)	2,205	(19)	1,093
Licensing costs	(6,467)	-	-	-	-
	(10,171)	(45)	2,176	(25)	1,064
Financing activities					
Proceeds from issuance of share capital	178,729	-	91	-	91
Repurchase of share capital	(3,552)	-	(989)	-	(953)
Share issue costs	(12,312)	-	-	-	-
	162,865	-	(898)	-	(862)
Foreign exchange gain on cash and cash equivalents held in foreign currency	4,399	1,550	1,239	1,381	(796)
(Decrease) increase in cash and cash equivalents	64,864	(22,962)	60,370	(10,865)	(10,648)
Cash and cash equivalents – Beginning of period	-	87,826	35,428	75,729	106,446
Cash and cash equivalents – End of period	64,864	64,864	95,798	64,864	95,798
Cash and cash equivalents consists of					
Bank accounts	1,282	1,282	1,261	1,282	1,261
Interest bearing deposits and securities	63,582	63,582	94,798	63,582	94,537
	64,864	64,864	95,798	64,864	95,798